# ![@CamillusMiura Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1957826312263098368.png) @CamillusMiura CamillusMiuraExp

CamillusMiuraExp posts on X about $evmn, $ocul, $sepn, $dmac the most. They currently have [--] followers and [--] posts still getting attention that total [-----] engagements in the last [--] hours.

### Engagements: [-----] [#](/creator/twitter::1957826312263098368/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1957826312263098368/c:line/m:interactions.svg)

- [--] Week [-----] +278%
- [--] Month [------] +306%

### Mentions: [--] [#](/creator/twitter::1957826312263098368/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1957826312263098368/c:line/m:posts_active.svg)

- [--] Week [--] +26%
- [--] Month [--] +103%

### Followers: [--] [#](/creator/twitter::1957826312263098368/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1957826312263098368/c:line/m:followers.svg)

- [--] Week [--] +25%
- [--] Month [--] +286%

### CreatorRank: [-------] [#](/creator/twitter::1957826312263098368/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1957826312263098368/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  50% [finance](/list/finance)  7.35% [technology brands](/list/technology-brands)  2.94% [countries](/list/countries)  1.47%

**Social topic influence**
[$evmn](/topic/$evmn) #4, [$ocul](/topic/$ocul) #6, [$sepn](/topic/$sepn) #1, [$dmac](/topic/$dmac) #1, [$incy](/topic/$incy) #4, [$lly](/topic/$lly) #173, [data](/topic/data) #619, [$gsk](/topic/$gsk) 5.88%, [$phvs](/topic/$phvs) 4.41%, [$acrs](/topic/$acrs) 4.41%

**Top accounts mentioned or mentioned by**
[@dustinpgreen](/creator/undefined) [@joserestonva](/creator/undefined) [@aafree](/creator/undefined) [@hothomaswphelps](/creator/undefined) [@johnhersc79276](/creator/undefined) [@minervacap](/creator/undefined) [@diamedica](/creator/undefined) [@idalopirdine](/creator/undefined) [@andersresearch](/creator/undefined) [@harvardmed](/creator/undefined) [@okyopharma](/creator/undefined) [@wangyuhung](/creator/undefined) [@learnbiotech](/creator/undefined) [@jl4nge](/creator/undefined) [@rudyresearch](/creator/undefined) [@treyhendrickzyn](/creator/undefined) [@themarketedgeai](/creator/undefined) [@sjfms1steven](/creator/undefined) [@thefullanalysis](/creator/undefined)

**Top assets mentioned**
[Evommune, Inc. (EVMN)](/topic/$evmn) [Ocular Therapeutix, Inc. (OCUL)](/topic/$ocul) [Septerna, Inc. (SEPN)](/topic/$sepn) [Incyte Corporation (INCY)](/topic/$incy) [Eli Lilly and Company (LLY)](/topic/$lly) [GSK plc (GSK)](/topic/$gsk) [Pharvaris, B.V. (PHVS)](/topic/$phvs) [Novartis AG (NVS)](/topic/$nvs) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [Celldex Therapeutics, Inc (CLDX)](/topic/$cldx) [Apogee Therapeutics, Inc. (APGE)](/topic/$apge) [Kymera Therapeutics, Inc. (KYMR)](/topic/$kymr) [Synthetify (SNY)](/topic/$sny) [Third Harmonic Bio, Inc. (THRD)](/topic/$thrd)
### Top Social Posts
Top posts by engagements in the last [--] hours

"A SubQ administration of EVO301 would be game changing. Main concern of adoption is the current IV route. $EVMN"  
[X Link](https://x.com/CamillusMiura/status/2021221144095850798)  2026-02-10T13:54Z [--] followers, [---] engagements


"Anyone remember when @Dustinpgreen and colleagues unveiled major functions of Mrgprb2/X2 six years ago out of Hopkins Awesome discovery Answered a lot of questions as to why NK-1 receptor antagonist studies were so disappointing. $EVMN $SEPN $LLY"  
[X Link](https://x.com/CamillusMiura/status/2005730292989104531)  2025-12-29T19:59Z [--] followers, [---] engagements


"$PHVS Deucrictibant has such a proven mechanism of action for hereditary angioedema (BDKRB2 antagonism) that any negative data release would be a surprise"  
[X Link](https://x.com/CamillusMiura/status/2008190983209619509)  2026-01-05T14:56Z [--] followers, [---] engagements


"$PHVS Only one trial of concern treating BK-AE-nC1INH patients (NCT07046806). Not questioning deucrictibant effectiveness just patient selection. Hard patient population to identify. Is a proprietary biomarker used for inclusion criteria"  
[X Link](https://x.com/CamillusMiura/status/2008222287204676045)  2026-01-05T17:01Z [--] followers, [---] engagements


"While $PHVS $KALV $BCRX and others are inhibiting the Bradykinin-Kallikrein System to treat HAE $DMAC is intentionally increasing bradykinin activity with DM199 after acute ischemic stroke to increase vasodilation. Penumbra blood flow paramount for stroke recovery. @diamedica"  
[X Link](https://x.com/CamillusMiura/status/2008588973166522481)  2026-01-06T17:18Z [--] followers, [---] engagements


"Because Regeneron's REGN2176-3 blocked both VEGF and PDGF but failed in a wet AMD trial it is unlikely that AXPAXLI's action on PDGFR is therapeutically significant. Clinical Trial ID: NCT02418754 $OCUL $REGN"  
[X Link](https://x.com/CamillusMiura/status/2012211108107477043)  2026-01-16T17:11Z [--] followers, [----] engagements


"Can $EVMN's EVO301 show similar efficacy to $CRVS's Soquelitinib in AD Different MoA but encouraging data from Apollo therapeutics' Camoteskimab in Anti IL-18 therapy for AD. $ACRS"  
[X Link](https://x.com/CamillusMiura/status/2013702420140839264)  2026-01-20T19:57Z [--] followers, [----] engagements


"Great graphic by Kobayashi on innate lymphoid cell (ILC) lines. ILC2s contribute to atopic dermatitis pathology. $CRVS $EVMN $ACRS $APGE $KYMR $NKTR"  
[X Link](https://x.com/CamillusMiura/status/2016174535360364922)  2026-01-27T15:40Z [--] followers, [----] engagements


"@JoseRestonVA @a_a_free @idalopirdine Is it because of the failure of EP-262 by $INCY"  
[X Link](https://x.com/CamillusMiura/status/2020271278150808007)  2026-02-07T22:59Z [--] followers, [---] engagements


"@HOThomasWPhelps What are your thoughts on $ACRS ATI-2138 compared to $CRVS soquelitinib Maybe you could direct me to a previous post of yours"  
[X Link](https://x.com/CamillusMiura/status/2021960802798899661)  2026-02-12T14:53Z [--] followers, [---] engagements


"@Anders_Research Have any thoughts on the novel MoA of MRGPRX2 inhibition for indications such as urticaria and atopic dermatitis $NVS $SEPN $ENTA $EVMN all have modulators in the pipeline"  
[X Link](https://x.com/CamillusMiura/status/2014353083329888530)  2026-01-22T15:02Z [--] followers, [---] engagements


"Earlier this year Allakos's AK006 failed to show efficacy in CSU. A Siglec-6 activator with downstream inhibitory effects on MRGPRX2 rasised concern for CSU and MRGPRX2 modulation. $EVMN $SEPN $LLY"  
[X Link](https://x.com/CamillusMiura/status/2001697308946346181)  2025-12-18T16:53Z [--] followers, [---] engagements


"MassGen uncovered another neuroinflammatory mechanism. Sensory neuron memory in allergic immunity. mTORC1 and the top [--] signature genes involved in the mTORC1 signaling pathway. [--] potential drug targets. $EVMN $SEPN $LLY $GSK @harvardmed"  
[X Link](https://x.com/CamillusMiura/status/2007074769540391171)  2026-01-02T13:01Z [--] followers, [---] engagements


"$ENTA expected to have an oral MRGPRX2 development candidate by 2H [----]. So early in development but so much potential $EVMN"  
[X Link](https://x.com/CamillusMiura/status/2009662971233108184)  2026-01-09T16:26Z [--] followers, [---] engagements


"Companies developing MRGPRX2 drugs. Not an inclusive list. Firm also considering Chinese and private development. $EVMN $ENTA $SEPN $INCY $NVS"  
[X Link](https://x.com/CamillusMiura/status/2010713985394364444)  2026-01-12T14:02Z [--] followers, [---] engagements


"Best expression of how $EYPT's and $OCUL's intravitreal TKIs could save payers massive amounts of money. Current frequency of aflibercept payment in black dots. All of the orange dots gray dots and one TKI injection is what they could pay in the future. Massive reduction"  
[X Link](https://x.com/CamillusMiura/status/2013837478965186615)  2026-01-21T04:54Z [--] followers, [----] engagements


"$OCUL SOL1 primary outcome of maintaining vision by [--] letters lost is going after patients who fall between the cracks of recuse or who stop responding to anti-VEGF therapy. Its a gamble for the superiority label over aflibercept. Rescue analysis likely positive though"  
[X Link](https://x.com/CamillusMiura/status/2022393965711102122)  2026-02-13T19:34Z [--] followers, [----] engagements


"If $DMAC ReMEDy1 had just one more placebo responder out of [--] patients and N=200 for ReMEDy2 then the chances of reaching statistical significance of primary outcome for ReMEDy2 is only at 40%. If N=728 (hopeful enrollment) then probability with same variability jumps to 90%"  
[X Link](https://x.com/anyuser/status/2017315361423585533)  2026-01-30T19:13Z [--] followers, [---] engagements


"For $DMAC Phase 2/3 ReMEDy2 trial 60% probability of interim data meeting primary outcome with statistical significance even though interim analysis will be underpowered. 80% probability that interim analysis will NOT lead to futility. DM for questions"  
[X Link](https://x.com/anyuser/status/2017325924778209734)  2026-01-30T19:55Z [--] followers, [---] engagements


"Biggest concern for $EVMN EVO756 chronic spontaneous urticaria (CSU) trial is the lack of efficacy shown in the $INCY EP-262 CSU trial another MRGPRX2 antagonist. UAS7 ISS7 and HSS7 score https://clinicaltrials.gov/study/NCT06077773intr=EP262&rank=2&tab=results#outcome-measures https://clinicaltrials.gov/study/NCT06077773intr=EP262&rank=2&tab=results#outcome-measures"  
[X Link](https://x.com/anyuser/status/2018312204240519363)  2026-02-02T13:15Z [--] followers, [---] engagements


"Interesting to note that the three patients who required rescue therapy while on Axpaxli prior to week [--] did NOT require an additional rescue dose. $OCUL $EYPT"  
[X Link](https://x.com/anyuser/status/2018452382766817660)  2026-02-02T22:32Z [--] followers, [----] engagements


"Great source for estimating initial ETDRS letter gain due to aflibercept injections in both treatment and control arms for $OCUL SOL-1 . First two injections show greatest gains. An estimated +2 letter gain from week [--] - [--] in control arm. https://www.aaojournal.org/article/S0161-6420(12)00865-2/fulltext#fig3 https://www.aaojournal.org/article/S0161-6420(12)00865-2/fulltext#fig3"  
[X Link](https://x.com/anyuser/status/2018683443572335089)  2026-02-03T13:50Z [--] followers, [----] engagements


"Congrats $EVMN on EVO301 results https://ir.evommune.com/news-events/press-releases/detail/119/evommune-announces-positive-top-line-data-from-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis https://ir.evommune.com/news-events/press-releases/detail/119/evommune-announces-positive-top-line-data-from-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis"  
[X Link](https://x.com/CamillusMiura/status/2021218296826056711)  2026-02-10T13:42Z [--] followers, [---] engagements


"Awesoome dose response by EVO301 in atopic dermatitis. $EVMN"  
[X Link](https://x.com/CamillusMiura/status/2021218910209454527)  2026-02-10T13:45Z [--] followers, [---] engagements


"Need to manufacture more was stated on investor call in reference to EVO301 SubQ formulation. Great news"  
[X Link](https://x.com/CamillusMiura/status/2021224376469766189)  2026-02-10T14:06Z [--] followers, [--] engagements


"$EVMN EVO756 for migraine investor call stated "we think the data may be even most compelling." This aligns with EVO756 mechanism of action as it targets neuro-immune interactions more specifically. Key in migraine pathophysiology"  
[X Link](https://x.com/CamillusMiura/status/2021233623748243481)  2026-02-10T14:43Z [--] followers, [---] engagements


"Looking forward to $SEPN SEP-631 phase [--] presentation at AAAAI on March 1st. A negative allosteric modulator of MRGPRX2 for the indication of CSU. Interested to see comparison to $EVMN EVO756 on icatibant challenge test. $EVMN results released in previous poster presentation"  
[X Link](https://x.com/CamillusMiura/status/2022070156390961269)  2026-02-12T22:07Z [--] followers, [---] engagements


"Great figure on current and future therapies for chronic spontaneous urticaria by Mathur et al. Pathways overlap with many indications such as atopic dermatitis and asthma. One therapy has potential for multiple indications. $NVS $CLDX $SNY $INCY $JSPR $EVMN $REGN $RHHBY $THRD"  
[X Link](https://x.com/CamillusMiura/status/2017255912759533908)  2026-01-30T15:17Z [--] followers, [---] engagements


"$OCUL Phase [--] SOL-1 data still masked. Will be presented at the Macula Society annual meeting end of February"  
[X Link](https://x.com/CamillusMiura/status/2019385228611969326)  2026-02-05T12:18Z [--] followers, [---] engagements


"Great paper on MRGPRX2s involvement in a mouse model (MRGPRB2) of atopic dermatitis. So much of the Nero-immune axis has yet to be uncovered. https://link.springer.com/content/pdf/10.1007/s00011-026-02184-y.pdf https://link.springer.com/content/pdf/10.1007/s00011-026-02184-y.pdf"  
[X Link](https://x.com/CamillusMiura/status/2020271781924483531)  2026-02-07T23:01Z [--] followers, [---] engagements


"My model for $OCUL produced a 52.5% probability of success in meeting the primary outcome. This study could be make or break based on secondaries"  
[X Link](https://x.com/CamillusMiura/status/2020983668450197577)  2026-02-09T22:10Z [--] followers, [---] engagements


"EVO301 $EVMN has a strong comparison with current FDA approved competitors for stopic dermatitis. Note this is only [--] weeks of treatment for EVO301 NOT [--] weeks"  
[X Link](https://x.com/CamillusMiura/status/2021220552627659198)  2026-02-10T13:51Z [--] followers, [---] engagements


"I didnt know it would take $OCUL [--] new hires to restructure for bankruptcy. https://www.linkedin.com/jobs/search/currentJobId=4332739755&f_C=2698971&geoId=92000000&origin=COMPANY_PAGE_JOBS_CLUSTER_EXPANSION&originToLandingJobPostings=4361354904%2C4372739348%2C4368408814%2C4364021482%2C4361391208%2C4367159414%2C4367342296%2C4365375699%2C4332739755"  
[X Link](https://x.com/CamillusMiura/status/2022768690890981753)  2026-02-14T20:23Z [--] followers, [----] engagements


"$EVMN Fascinating data from EVO756 Phase [--] chronic inducible urticaria trial. Three responder subgroups. Complete responder group most exciting. Can we find a biomarker to identify these patients"  
[X Link](https://x.com/CamillusMiura/status/2001364933251076302)  2025-12-17T18:52Z [--] followers, [---] engagements


"Bravo to $INCY for posting INCB000262/EP-262 data of their failed Phase [--] data for CSU IDNCT06077773). It's a blow for MRGPRX2 modulation. I hope $EVMN can avoid the same blunder. http://ClinicalTrials.gov http://ClinicalTrials.gov"  
[X Link](https://x.com/CamillusMiura/status/2001369038312870006)  2025-12-17T19:08Z [--] followers, [---] engagements


"$OKYO With improvement of total nerve fiber count in their phase [--] trial for NCP it would be a game changer if urcosimod could provide objective data for pain improvement in a phase [--] trial"  
[X Link](https://x.com/CamillusMiura/status/2001422996846661856)  2025-12-17T22:43Z [--] followers, [---] engagements


"Could a breakthrough in neurogenic inflammation come from this compound $EVMN $LLY"  
[X Link](https://x.com/CamillusMiura/status/2001672601937080670)  2025-12-18T15:15Z [--] followers, [---] engagements


"@OkyoPharma congrats to Gabriele Cerrone on opening the markets. Looking forward to more data on your chimeric receptor agonist Urcosimod. $OKYO"  
[X Link](https://x.com/CamillusMiura/status/2002022113985577305)  2025-12-19T14:24Z [--] followers, [--] engagements


"Apollo Therapeutics camoteskimab turned the tide in IL-18 targeted therapy. Could $EVMN EVO301 follow suit Key chemical differences between the two"  
[X Link](https://x.com/CamillusMiura/status/2002026214975033345)  2025-12-19T14:40Z [--] followers, [---] engagements


"Anyone remember when @Dustinpgreen and colleagues unveiled major functions of Mrgorb2/X2 six years ago out of Hopkins Awesome discovery Answered a lot of questions as to why NK-1 receptor antagonist studies were so disappointing. $EVMN $SEPN $LLY"  
[X Link](https://x.com/CamillusMiura/status/2005726213810307179)  2025-12-29T19:42Z [--] followers, [--] engagements


"I love how $OKYO's urcosimod has helped patients with corneal neuropathic pain but concerned about identifying the right patients. Many pathophysiological reasons as to why some patients may not respond. e.g. central pain sensitization when urcosimod is topical (peripheral)"  
[X Link](https://x.com/CamillusMiura/status/2008554472163995827)  2026-01-06T15:01Z [--] followers, [---] engagements


"RT @Wang_Yu_Hung: #JAK is the future. Pharmacological targeting of the JAKSTAT pathway: new concepts and emerging indications https://t"  
[X Link](https://x.com/CamillusMiura/status/2011442095769501871)  2026-01-14T14:15Z [--] followers, [--] engagements


"Depending on the intravitreal concentrations of axitinib released from AXPAXLI axitnib may not meaningfully suppress PDGFRs. $OCUL"  
[X Link](https://x.com/CamillusMiura/status/2011851641016721657)  2026-01-15T17:23Z [--] followers, [---] engagements


"@john_hersc79276 That makes a lot of sense. The question I ask now is not about comparative efficacy to market leaders (likely fall short) but who is the patient that would need this type of treatment I suppose patients willing to compromise on efficacy in order to receive less injecitons"  
[X Link](https://x.com/CamillusMiura/status/2012362564508787094)  2026-01-17T03:13Z [--] followers, [--] engagements


"@john_hersc79276 That phase 2b study looks good"  
[X Link](https://x.com/CamillusMiura/status/2012371369741140067)  2026-01-17T03:48Z [--] followers, [--] engagements


"After reviewing the FDA's AdCom on brexpiprazole/sertaline combination therapy for PTSD the expert clinicians recognized this treatment as already "in the toolbox" but it seemed they didn't like the idea of endorsing as first line therapy. Is Otsuka just sitting on it"  
[X Link](https://x.com/CamillusMiura/status/2013283855961055480)  2026-01-19T16:14Z [--] followers, [---] engagements


"@learnbiotech This is solid. $DMACs DM199 has the first two down now just going after the proof of concept. Interim phase [--] data for preeclampsia out of South Africa looking good so far. FDA expected to start after a preclinical study wraps up"  
[X Link](https://x.com/CamillusMiura/status/2015778419414368735)  2026-01-26T13:26Z [--] followers, [--] engagements


"IL-18 therapy Mexican standoff. EVO301 may be more structurally related to Tadekinig alfa (IL-18BP like EVO301) than camoteskimab but tadekinig alfa structure not explicit. $EVMN Past IL-18 failures not included"  
[X Link](https://x.com/CamillusMiura/status/2003154925392699661)  2025-12-22T17:25Z [--] followers, [---] engagements


""Observe record tabulate communicate." - Sir William Osler (Father of modern medicine). When a medical paper simply adheres to these principles it's a breath of fresh air. #McGill #JohnsHopkins"  
[X Link](https://x.com/CamillusMiura/status/2009265357077283050)  2026-01-08T14:06Z [--] followers, [---] engagements


"With a molecular weight of [----] kDa it is unlikely that DM199 would cross the placental barrier. This supports a positive outlook for preclinial data of DM199 in a rabbit model evaluating safety of embryo and postnatal development. $DMAC Results expected by 2nd quarter"  
[X Link](https://x.com/CamillusMiura/status/2009374274394488893)  2026-01-08T21:18Z [--] followers, [---] engagements


"Great TKI summary for wet AMD by Amin and Kaiser. Clearly shows the sound mechanism of action of AXPAXLI (axitinib in figure). Axitnib is "behind enemy lines" suppressing VEGFR and PDGFR activity intracellularly. $OCUL"  
[X Link](https://x.com/CamillusMiura/status/2011089968307847193)  2026-01-13T14:56Z [--] followers, [---] engagements


"Im sincerely grateful for biopharma failures R&D work just to find what doesnt work. This has contributed to so many successful treatments"  
[X Link](https://x.com/CamillusMiura/status/2016175099204809061)  2026-01-27T15:42Z [--] followers, [--] engagements


"The MoA of $DMAC DM199 for preeclampsia is seriously ingenious. Using kallikrein to reduce blood pressure in pregnant mothers. So many reasons as to why this is such a good idea. Who came up with this one"  
[X Link](https://x.com/CamillusMiura/status/2016180524335645007)  2026-01-27T16:04Z [--] followers, [---] engagements


"$CLDX Had great Phase1b study results for chronic inducible urticaria back in [----]. Most impressive is how every patient responded to barzolvolimab (red circle). Small N but impressive none the less"  
[X Link](https://x.com/CamillusMiura/status/2014391803017937201)  2026-01-22T17:36Z [--] followers, [---] engagements


"For IL-18 targeted therapy Apollo Therapeutics Camoteskimab nudged out GSK's Aletekitug (GSK-1070806) in atopic dermatitis EASI-75 responder rates: 65% vs 36.8%. Variations between studies and post hoc analysis are not explicit. $GSK $EVMN"  
[X Link](https://x.com/CamillusMiura/status/2005856105499410639)  2025-12-30T04:18Z [--] followers, [---] engagements


"Will the PK of EVO301 decide the fate of upcoming Phase [--] data Aletekitug showed positive results in phase [--]. EVO301 has high affinity for the same target and reason to suspect similar tissue distribution. Phase [--] could show similar positive results $EVMN $GSK"  
[X Link](https://x.com/CamillusMiura/status/2007109859213521125)  2026-01-02T15:20Z [--] followers, [---] engagements


"@MinervaCap $EVMN EVO301 Phase [--] data should be out soon and two similar drugs showed positive phase [--] results for the same indication atopic dermatitis. Any thoughts on upcoming catalysts for $EVMN"  
[X Link](https://x.com/CamillusMiura/status/2007542830462578896)  2026-01-03T20:01Z [--] followers, [---] engagements


"@MinervaCap Yes Agree with EVO301 as de-risked. EVO756s mechanism of action is pure gold. Ive followed it for years. BUT can $EVMN dig up the gold with a proper trial $INCY wasnt able to pull it off"  
[X Link](https://x.com/CamillusMiura/status/2008165296494858575)  2026-01-05T13:14Z [--] followers, [---] engagements


"In anti IL-18 trials GSKs GSK1070806 Aletekitug was safe overall in Phase [--] trial NCT04975438 but Tadekinig Alfa phase [--] trial with Three serious AEs occurred one possibly related to treatment (toxic optic neuropathy) $GSK $EVMN"  
[X Link](https://x.com/CamillusMiura/status/2008211105563222394)  2026-01-05T16:16Z [--] followers, [---] engagements


"@JL4NGE Three data readouts expected this year for $EVMN. I suspect the EVO301 atopic dermatitis readout in H2 [----]. Two competitors have already supported the Anti-IL-18 mechanism of action for the same indication. Still molecular differences need to be taken into account"  
[X Link](https://x.com/CamillusMiura/status/2009279743066021983)  2026-01-08T15:03Z [--] followers, [---] engagements


"@RudyResearch Yes Ive been following this mechanism of action for years. A lot of companies are going after MRGPRX2. $INCY failed their trial but $EVMN showed good phase [--] data for a different indication prior to IPO"  
[X Link](https://x.com/CamillusMiura/status/2012227302063583733)  2026-01-16T18:15Z [--] followers, [---] engagements


"@TreyHendrickzyn No elevations in the lower dose [--] mg BID treatment group. Could even argue better efficacy in the lower dose group. If $EVMN sticks with lower dosing then not worried but definitely keeping an eye on it. Other clues point towards lower dosing as better therapeutically"  
[X Link](https://x.com/CamillusMiura/status/2012258157330825264)  2026-01-16T20:18Z [--] followers, [---] engagements


"@a_a_free @JoseRestonVA @HOThomasWPhelps That trial helped de-risk anti IL-18 therapy. Along with $GSKs Aletekitug https://clinicaltrials.gov/study/NCT04975438intr=GSK1070806&rank=4&tab=results#outcome-measures https://clinicaltrials.gov/study/NCT04975438intr=GSK1070806&rank=4&tab=results#outcome-measures"  
[X Link](https://x.com/CamillusMiura/status/2014820001589445053)  2026-01-23T21:58Z [--] followers, [--] engagements


"@TheMarketEdgeAI $EVMN and obesity"  
[X Link](https://x.com/CamillusMiura/status/2016995912728399979)  2026-01-29T22:04Z [--] followers, [---] engagements


"Great table of current TKI drugs for wetAMD by Amin and Kaiser. The private company AiViva showed a [--] letter gain BUT only five patients and only one with wetAMD. Other four with DME. Most TKIs show BCVA stability. $OCUL $EYPT"  
[X Link](https://x.com/CamillusMiura/status/2013722758945837436)  2026-01-20T21:18Z [--] followers, [----] engagements


"How many payers would rather reduce aflibercept injection frequency with anti-VEGF gene therapy $RGNX compared to one or two TKI injections per year $OCUL $EYPT"  
[X Link](https://x.com/CamillusMiura/status/2014746655438811415)  2026-01-23T17:06Z [--] followers, [----] engagements


"If $DMAC ReMEDy2 effect size stays the same as ReMEDy1 then ReMEDy2 is simulated to have an 80% chance of meeting primary outcome"  
[X Link](https://x.com/CamillusMiura/status/2017314723558031512)  2026-01-30T19:11Z [--] followers, [---] engagements


"$DMAC ReMeDy2 relies heavily on number of patients enrolled in order to meet primary outcome"  
[X Link](https://x.com/CamillusMiura/status/2017315928891924510)  2026-01-30T19:16Z [--] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing